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Mammalian aging is accompanied by a progressive loss of skeletal muscle, a process called sarcopenia. Myostatin, 
a secreted member of the transforming growth factor-β family of signaling molecules, has been shown to be a potent 
inhibitor of muscle growth. Here, we examined whether muscle growth could be promoted in aged animals by antagoniz-
ing the activity of myostatin through the neutralizing activity of the myostatin propeptide. We show that a single injec-
tion of an AAV8 virus expressing the myostatin propeptide induced an increase in whole body weights and all muscles 
examined within 7 weeks of treatment. Our cellular studies demonstrate that muscle enlargement was due to selective 
fiber type hypertrophy, which was accompanied by a shift toward a glycolytic phenotype. Our molecular investigations 
elucidate the mechanism underpinning muscle hypertrophy by showing a decrease in the expression of key genes that 
control ubiquitin-mediated protein breakdown. Most importantly, we show that the hypertrophic muscle that develops 
as a consequence of myostatin propeptide in aged mice has normal contractile properties. We suggest that attenuating 
myostatin signaling could be a very attractive strategy to halt and possibly reverse age-related muscle loss.
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SKELETAL muscle is a highly compliant tissue that undergoes both quantitative and qualitative changes 
as part of an adaptive process to environmental and physi-
ological stimuli. Skeletal muscle not only serves to produce 
movement both for locomotion and for the maintenance of 
posture but also plays a significant role in the metabolic 
functioning of the body. It also serves as a reservoir of pro-
teins and, working in concert with the liver, acts to control 
the concentrations of both glucose and amino acids in the 
circulation (1). A  diminution of either the locomotory or 
metabolic roles in humans leads to a severe attenuation in 
the quality of life and the predisposition to a number of dis-
eases including diabetes.
The increase in the longevity of individuals in Western 
societies will present considerable challenges to the health 
care and economic systems of developed countries as they 
care for people whose body functions undergo age-related 
deterioration. Old age is associated with a progressive loss 
of skeletal muscle mass, a process called sarcopenia (2). 
Sarcopenia leads to lack of muscle strength and increased 
fatigability (3), resulting in reduced posture and mobility, 
increased risk of falls. These factors all contribute to a 
decrease in quality of life. At the cellular level, sarcopenic 
skeletal muscle undergoes progressive muscle fiber atrophy 
(4) with some evidence for the loss of fast glycolytic fib-
ers (5) and increase in fat and connective tissue (6). At the 
subcellular level, aged muscle fibers display an increased 
level of mitochondrial abnormalities and susceptibility to 
apoptosis. In humans, sarcopenia first becomes evident at 
middle age. Large population studies have reported that 
more than 20% of 60- to 70-year olds have sarcopenia and 
that the number reaches 50% in those aged 75 and older 
(7). The number of people likely to be affected by sarcope-
nia will increase dramatically since Western society popu-
lations are aging fast, with statisticians predicting that the 
proportion of people older than 60 years may rise by 40% 
in the next 30 years. The present burdens on the health care 
systems to care for individuals suffering from sarcopenia 
are already huge, estimated to have been about $18.5 bil-
lion in 2000, a sum that will increase greatly as number of 
people afflicted by sarcopenia rises due to aging popula-
tions (8). It is, therefore, not surprising that a considerable 
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effort is being expended to develop antisarcopenic thera-
pies. A number of different strategies have been proposed 
to halt and/or reserve the adverse effects of sarcopenia. One 
tranche of research has focused on augmentative programs 
that normally promote muscle growth, which have included 
an axis revolving around insulin-like growth factor-1 sign-
aling or testosterone-mediated action (9).
In contrast, we and others have focused on develop-
ing muscle growth programs based on attenuating signal-
ing mechanisms that usually inhibit muscle development. 
One of the most potent inhibitors of muscle development is 
myostatin, a member of the transforming growth factor-β 
superfamily of secreted proteins (10). The role of myostatin 
has been extensively studied in numerous mammalian spe-
cies including cattle, mice, sheep, dogs, and, in one case, in 
man. In all cases, inactivation of myostatin results in mus-
cle enlargement through myofiber hypertrophy or hyper-
plasia or both, together with a reduction in adipose tissue 
content (11–13). Myostatin initiates an intracellular sign-
aling cascade by firstly binding the extracellular domain 
of the activin type II receptor, which leads to the recruit-
ment and activation of the activin receptor–like kinases 4 
and 5.  At least two intracellular signaling cascades have 
been described that are activated through phosphorylation 
mediated by the activin receptor–like kinases. Canonical 
for transforming growth factor-β signaling is the activa-
tion by phosphorylation of Smad2/3, enabling an interac-
tion with Smad4 that facilitates entry into the nucleus to 
activate gene transcription (14). Myostatin can also initiate 
signaling without the involvement of the Smad2/3 pathway 
by inhibiting the phosphorylation of Akt, which, in skeletal 
muscle, acts as nodal point controlling cell proliferation, 
protein synthesis, and protein catabolism either through 
the proteasome or autophagy (15). In agreement with its 
proposed role as being an inhibitor of muscle develop-
ment, overexpression of myostatin causes muscle loss (16). 
Higher concentrations of myostatin have been detected in 
many pathological conditions in which muscle loss is a cen-
tral feature including HIV and myocardial infarct (reviewed 
by Matsakas and Diel (17)).
Insights into the mechanisms that control posttransla-
tional modification of myostatin have revealed avenues 
that permit its neutralization. A  key feature is that it is 
synthesized as an inactive precursor protein, in which an 
N-terminal propeptide (MyoPPT) is linked via a peptide 
bond to the C-terminal biologically active region (18). The 
C-terminal portion only becomes biologically active upon 
proteolytic processing. However, the MyoPPT is able to 
associate with of the C-terminal peptide causing a rever-
sion to the latent state (19). We have used this property 
of the MyoPPT to induce myogenic growth in the whole 
animal through single injection of adeno-associated virus 
(AAV) serotype 8 (AAV8)-mediated delivery system into 
young mice and demonstrated that muscle grew by 55% 
within 17 weeks (20). Importantly, our virally mediated 
overexpression of the MyoPPT resulted in the development 
of many of the phenotypes displayed by the myostatin null 
mouse, including fiber hypertrophy. Notably in contrast 
to the myostatin null mouse, the hypertrophic muscle that 
formed as a consequence of MyoPPT treatment displayed 
normal levels of specific tension in muscle (21).
Myostatin concentration has been reported to increase 
in elderly men and women, especially in those showing 
muscle wasting (22,23). We hypothesize that these elevated 
concentrations are responsible for age-related muscle loss, 
and that the MyoPPT will halt the muscle wasting process 
through its neutralizing activity.
Here, we show that 20-month-old mice given a single 
injection of MyoPPT resulted in extensive muscle growth 
within 7 weeks. We provide evidence that muscle mass 
increased due to a normalization of key genes that con-
trol ubiquitin-mediated protein breakdown to levels found 
in young adult mice. Most importantly, we show that the 
hypertrophic muscle that developed following MyoPPT 
treatment was able to generate normal levels of tetanic ten-
sion commensurate with its mass.
Methods
Ethical Approval
Animal work was performed under license from the UK 
Home Office in agreement with the Animals (Scientific 
Procedures) Act 1986 and complied with the policy and 
regulations of the journal.
Animal Maintenance
Healthy male C57Bl/6 mice were bred and maintained 
according to the NIH Guide for Care and Use of Laboratory 
Animals, approved by the University of Reading in the 
Biological Services Unit of Reading University. Mice of 
either 4 or 20 months old were used for the study. Mice 
were housed under standard environmental conditions (20–
22°C, 12:12-hour light–dark cycle) and provided food and 
water ad libitum.
Vector Generation
A fragment coding for the modified version of MyoPPT 
was ligated to cDNA for the mouse IgG2a moiety (18) and 
cloned into a pDD-derived AAV plasmid under the control 
of the CAGGs promoter (24). The IgG2a moiety prolongs 
the half-life of recombinant protein but does not affect mus-
cle growth. All viruses were titered by Nantes Vector Core, 
France.
Recombinant AAV Administration
To facilitate the injection process, mice were kept at 40°C 
for 10 minutes to induce vasodilation prior to injection. Six 
mice at 20 months of age were injected via the tail vein with 
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2 × 1011 vector genomes (AAV8ProMyo). Animals injected 
with empty vector served as the untreated group. Wherever 
indicated, a second control group of 10 young male mice (4 
months old) was also examined. Five AAV8ProMyo treated 
and six animals were weighed at weekly intervals (except 
Week 6)  for 7 weeks after injection (one AAV8ProMyo-
treated animal was not weighed weekly due to administra-
tive oversight). Physiological and histological assessments 
were performed at 7 weeks following recombinant AAV8 
administration.
Detection of transgene Expression From Blood Plasma 
Samples
Tail vein bleeds (75 µL) were taken at 1, 4, and 7 weeks 
post-administration of recombinant AAV8 and used to assess 
transgene expression through western blotting. Plasma sam-
ples were diluted in phosphate-buffered saline (1:150), of 
which 5 µL was denatured in sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis sample buffer followed by 
heating at 100°C for 5 minutes. Proteins were resolved using 
a 4%–12% SDS–NuPAGE (Invitrogen/Novex, Groningen, 
The Netherlands), prior to blotting onto a ECL-nitrocellulose 
membrane (Amersham Pharmacia Biotech, UK). Membranes 
were incubated with goat anti-mouse IgG2a antibody (1:50 
dilution; AbD Serotec, UK) followed by an anti-goat horse-
radish peroxidase secondary antibody (1:3,000 dilution; 
Sigma, UK). Blots were developed using the ECL detec-
tion system (Amersham Pharmacia Biotech). Endogenous 
myostatin or MyoPPT are not detected with this method.
Histological Analysis
Mice were killed according to Schedule 1 of the Animals 
Scientific Procedures Act (United Kingdom) prior to the dis-
section of muscle of interest, were weighed, and then were 
frozen in liquid nitrogen–cooled isopentane. Frozen muscles 
were mounted in Tissue Tech freezing medium (Jung) in dry 
ice–cooled ethanol. Immunocytochemistry was carried out 
on 10-µm transverse cryosections by firstly air drying for 30 
minutes and then blocking in wash buffer (phosphate-buffered 
saline containing 5% fetal calf serum [vol/vol], 0.05% Triton 
X-100). All antibodies were diluted in wash buffer 30 min-
utes before use. Myosin heavy chain (MHC) type I, IIA, and 
IIB isoforms were identified by using A4.840 IgM (1:1 dilu-
tion), A4.74 IgG (1:4 dilution), and BF-F3 IgM (1:1 dilution) 
supernatant monoclonal primary antibodies (Developmental 
Studies Hybridoma Bank). Mouse monoclonal antibody 
against Collagen I from Abcam was used at concentrations 
of 1:500 for immunohistology. Primary antibodies were visu-
alized using Alexa Fluor 488 goat anti-mouse IgG (1:200; 
A11029, Molecular Probes) and Alexa Fluor 633 goat anti-
mouse IgM (1:200; A21046, Molecular Probes) secondary 
antibodies. Muscle fiber oxidative capacity was determined 
by using an succinate dehydrogenase (SDH) staining proto-
col as described previously (25).
Quantitative PCR
Promega SV Total RNA Isolation kit was used to pre-
pare total RNA from the tibialis anterior muscle (TA) 
which served as the template for cDNA synthesis gener-
ated with Invitrogen SuperScript III Reverse Transcriptase. 
Quantitative real-time reverse transcription–PCR was per-
formed using Qiagen QuantiTect SYBR Green PCR Kit. All 
data were normalized to GAPDH expression. Primers were 
designed using the software Primer Express 3.0 (Applied 
Biosystems) and are listed in Supplementary Table 5.
Muscle tension Measurements
Dissection of the hind limb was carried out under oxy-
genated Krebs solution (95% O
2
 and 5% CO
2
). A silk suture 
was tied to the distal tendon of the extensor digitorum lon-
gus (EDL) with the proximal tendon being left attached 
to the tibial bone. The leg was pinned to a Sylgard-coated 
experimental chamber flooded with circulating oxygenated 
Krebs solution. The silk suture tied to the distal EDL tendon 
was attached a force transducer (Grass Telefactor FT03). 
Two silver electrodes were positioned longitudinally on 
either side of the EDL. The muscle was directly stimulated 
using an isolated constant voltage stimulator (S48, Grass 
Telefactor). The EDL was stretched to attain the optimal 
muscle length, which produced maximum twitch tension 
(P
t
). Tetanic contractions were provoked by stimulus trains 
of 500-millisecond duration at 10, 20, 50, 100, and 200 Hz. 
The maximum tetanic tension (P
0
) was determined from the 
plateau of the frequency–tension relationship.
Cross-sectional Area Measurements
Immunofluorescently stained muscle sections were pho-
tographed under a 10× lens on a Zeiss Axioimager A1 micro-
scope using a Zeiss Axiocam Mrm camera. Three different 
photographs were then taken at random on three different 
sections per muscle per animal. The interactive measure-
ments tool in the Axiovision Rel 4.8 software was then used 
to process the images to measure their cross-sectional area 
(CSA). All muscle fibers per fiber type were measured per 
field of view of the photographs taken (~200 in total).
Statistical Analysis
Data are presented as mean ± SD. Significant differences 
on body weight between groups were determined using mul-
tivariate analysis of variance followed by Bonferroni’s post 
hoc test with repeated measurements with time. Wherever 
applicable, comparisons between two groups were per-
formed by Student’s t test for independent variables. 
Differences among groups (old control, old PPT treated, 
and young control) were analyzed by one-way analysis of 
variance followed by Bonferroni’s multiple comparison 
tests. Differences were considered statistically significant 
at p < .05.
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Results
Single Systemic Injection of AAV8 Virus Expressing 
Modified Propeptide (AAV8MyoPPt) Results in an 
Increase in Body and Muscle Mass of Aged Mice
Male C57bl/6 mice (aged 20 months; n = 6) were injected 
with 2 × 1011 vector genomes expressing a stabilized form 
of the MyoPPT (AAV8MyoPPT). Western blot analysis 
was used to determine the onset of MyoPPT expression. 
A strong band of the correct molecular weight was detected 
in the plasma of animals at all time-points examined com-
mencing from 1 week after injection (data not shown).
The mean body weights were measured for five out of six 
treated mice and all control mice (n = 6) during the 7 weeks 
of the experiment (save Week 6). During the course of the 
study, the control-treated animals showed no significant 
increase in body mass (Figure 1A and B). In contrast, the 
AAV8MyoPPT-treated mice were 22% heavier than their 
starting weights at the end of the study (Figure 1A and B). 
Significant mass increase between the treated and control 
animals were statistically detectable from Week 5 onwards 
(Figure 1B; Supplementary Table 1).
We next examined the weights of tissues in the two 
cohorts to explain body mass differences. There were no 
significant differences in the weights of either the fat pads 
or the heart between the two groups when normalized to 
body mass. However, there were increases in the weights of 
all four muscle groups investigated (soleus, TA, gastrocne-
mius, Figure 1C–F and Supplementary Table 2, n = 6 for the 
treated group but not in the controls). We found an apparent 
muscle-specific response to AAV8MyoPPT with the EDL 
showing the largest gain in mass (21.42%) and the TA with 
the smallest increase (6.48%).
Muscle Enlargement Following AAV8MyoPPt 
Administration Is Caused by Fiber Hypertrophy
Next, we determined the reason underpinning the 
increase in muscle mass caused by AAV8ProMyo. To that 
end, we profiled fiber number, myosin heavy chain–specific 
fiber type size, and fiber type frequency. We found no evi-
dence for changes in fiber number due to the treatment in 
soleus, EDL, or TA (data not shown). Having found no 
evidence for an increase in fiber number, we next exam-
ined the CSA of fibers in a representative muscle of fast 
and slow phenotype (EDL and soleus, respectively). There 
were no type I fibers in the EDL of either the control or 
treated group. Furthermore, there were no significant dif-
ferences in the CSA of either type IIA or IIX fibers between 
AAV8MyoPPT-treated and control mice (Figure 2A and B; 
Supplementary Table 2a). However, we were able to detect 
a significant increase of 9.52% in the CSA of type IIB fibers 
of the EDL following AAV8MyoPPT injection (Figure 2C; 
Supplementary Table 2a). This change was muscle specific 
as we found that the soleus had undergone a different set 
of changes in response to AAV8MyoPPT. Here, the treat-
ment caused a significant decrease in type I  fibers CSA 
(Figure  2D; Supplementary Table  2b) but an increase in 
the CSA of both the (significant) type IIA (Figure 2E) and 
(nonsignificant) IIX fibers (Figure 2F). It is also noteworthy 
that we found an average of 7.3 fibers that were clearly type 
IIB in the treated group, a feature that was absent in the 
soleus of the control cohort.
We next investigated the effect of AAV8MyoPPT on fiber 
type distribution at both the metabolic level and in terms of 
myosin heavy chain isoform expression. We found a signifi-
cant decrease of 11.41% in the number of oxidative fibers 
judged by the expression of SDH in the treated EDL mus-
cle (Figure 2G–I; Supplementary Table 2d). However, we 
found no evidence of changes in myosin heavy chain expres-
sion profile in either the EDL (Figure 2J; Supplementary 
Table 2c) or soleus apart from the appearance of the few 
type IIB in the latter muscle as mentioned previously. We 
next investigated if there was any difference in the con-
nective tissue following treatment with the myostatin 
propeptide. Immunofluorescent staining of EDL sections 
for type I collagen revealed there to be no obvious differ-
ence between the old control and the old PPT-treated mice 
(Figure 2K and L). These results show that the increase in 
muscle mass following to AAV8MyoPPT treatment is not 
caused by an increase in fiber number but instead due to 
an enlargement of the fast fibers. Furthermore, a qualita-
tive change was additionally unveiled at least in the EDL 
muscle following AAV8MyoPPT treatment with a decrease 
in the proportion of fibers expressing SDH. However, 
this change in the metabolic status of the muscle was not 
reflected with changes in the expression of myosin heavy 
chain. Additionally, unlike in the genetic mutant, there was 
no change in the endomysial connective tissue compart-
ment following AAV8MyoPPT treatment (26).
Molecular Evidence for Decreased Proteasome-
Mediated Polypeptide Breakdown Following 
AAV8MyoPPt Administration in Aged Mouse
We next examined key markers that would inform on the 
status of protein breakdown through the proteasome or via 
autophagy in the TA muscle, which due to its size allows the 
isolation of a large amount of high-quality RNA needed for 
our comprehensive molecular profiling.
We examined changes in genes associated with protein 
breakdown, which may explain muscle enlargement follow-
ing AAV8MyoPPT administration. We firstly found that the 
expression of FoxO1, a molecule that promotes the break-
down of protein through both proteasome-mediated poly-
peptide degradation and autophagy (27,28), was elevated 
in aged muscle compared with young muscle. However, 
treatment of old mice with AAV8MyoPPT reduced the con-
centrations to those found in young muscle (Figure  3A). 
Subsequently, we examined the response of proteasome 
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and autophagic pathways to AAV8MyoPPT treatment. 
We found that the two key ubiquitin ligases, MuRF1 and 
Atrogin-1, induced by FoxO1 (27) that promote muscle 
protein breakdown were more abundant in old muscle com-
pared with younger tissue (Figure  3B and C). However, 
AAV8MyoPPT treatment decreased the expression of both 
MuRF1 and Atrogin-1 to the concentrations found in young 
muscle (Figure 3B and C).
Next, we profiled key regulators of autophagy in the TA 
muscles from old untreated and AAV8MyoPPT-treated 
samples and compared these to concentrations expressed 
in young muscle. Here, we studied Bnip3 (inducer of 
autophagy (29)), Beclin (which promotes the develop-
ment of the autophagosome, the double membrane vacu-
ole that develops around structures targeted for breakdown 
(30)), LC3b (protein that controls the development of the 
Figure 1. Myostatin propeptide affects whole body and muscle mass in aged mice. (A) Myostatin propeptide treatment increases the body mass of aged animals 
over a 7-week period (multivariate analysis of variance [MANOVA]; *p < .05) (n = 5 old AAV8ProMyo treated, n = 6 old control). (B) Myostatin propeptide signifi-
cantly increased total body mass from 4 weeks after treatment (MANOVA; *p < .05) (n = 5 old PPT AAV8ProMyo treated, n = 6 old control). Myostatin propeptide 
treatment increased mass of (C) EDL, (D) soleus, (E) tibialis, and (F) gastrocnemius after 7 weeks (*p < .05). EDL = extensor digitorum longus; PPT = propeptide.
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membrane component of the autophagosome through its 
ability to undergo lipidation with phosphatidylethanolamine 
(31)), ATF4 (cysteine protease responsible for cleaving LC3 
at its C-terminal arginine residue facilitating the exposed 
C-terminal glycine to be conjugated to phosphatidyletha-
nolamine (32)), cathepsin L (key lysosomal cysteine endo-
peptidase required for the degradation of autophagosomal 
content (33)), Vsp34 (Class III phosphoinositide-3-kinase 
Figure 2. Myostatin propeptide injection in aged mice and muscle fiber characteristics. (A) Type IIA and (B) type IIX fibers of the EDL did not alter in size 
to a significant degree following myostatin propeptide treatment. (C) Type IIB fibers of the EDL underwent hypertrophy due to myostatin propeptide treatment 
(*p < .05). (D) Soleus type I fibers decreased in size following propeptide treatment (*p < .05). (E) Type IIA fibers of the soleus underwent myostatin propeptide–
mediated hypertrophy (*p < .05). (F) Type IIX fibers of the soleus were unaffected by myostatin propeptide treatment. (G) Myostatin propeptide resulted in a decrease 
in the number of SDH-positive fibers in the EDL. (H) SDH activity in old control EDL muscle and (I) old AAV8ProMyo-treated EDL muscle. (J) Fiber type profiling 
of EDL muscle from control and AAV8ProMyo-treated animals. No statistically significant changes were detected following treatment. (K) Collagen I staining in old 
control EDL muscle and (L) old AAV8ProMyo-treated EDL muscle. Scale bar = 500 µm (H and I). Scale bar = 50 µm (K and L). EDL = extensor digitorum longus; 
PPT = propeptide; SDH = succinate dehydrogenase.
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[PI3K] that assembles into multiprotein complexes that 
include Beclin-1 (34)), and p62 (receptor for cargo destined 
to be degraded by autophagy (35)). However, there was 
no general consensus in terms of expression level differ-
ences between young and old muscle (Figure 3D, E, and 
G–I). Secondly, even when a difference did exist, for exam-
ple, for LC3b and p62 (Figure  3F and J), the concentra-
tions of the autophagic markers were unaltered following 
AAV8MyoPPT treatment. The only marker of autophagy 
that did not follow this trend was Gadd34 (which induces 
autophagy through the suppression of the mTOR pathway 
(36)) whose expression was normalized to that of young 
muscle following AAV8MyoPPT treatment (Figure 3K).
Muscle Enlargement Following AAV8MyoPPt treatment 
of Aged Mice and Muscle Contraction
Freshly isolated EDL muscles from untreated aged mice 
and treated mice were physiologically analyzed at 7 weeks 
post-AAV8MyoPPT injection. Our analysis revealed that 
maximum twitch tension was increased in treated muscle 
compared with controls but just failed to reach signifi-
cant levels (Figure 4A; Supplementary Table 4). However, 
the maximum tetanic force had increased significantly in 
older treated muscle (Figure 4C). Furthermore, when both 
the maximum twitch and maximum tetanic tensions were 
converted to specific values (taking into account muscle 
weights), there was no significant difference or even a trend 
toward a difference in the specific twitch or specific tetanic 
tensions between the AAV8MyoPPT-treated and aged con-
trol cohorts (Figure 4B and D). These results show that the 
extra muscle that develops following AAV8MyoPPT treat-
ment is functionally normal.
Conclusions
The prevalence of sarcopenia will increase in the Western 
world as the control of disease and better nutrition leads 
to increased life span. Although specific dietary regimes 
and exercise have been shown to attenuate sarcopenia, at 
present, we are unable to prevent it from occurring or to 
restore normal muscle mass following its onset. Many inter-
ventions have been proposed to control sarcopenia, but to 
date, all have only limited success or are accompanied by 
harmful side effects.
Increasing muscle mass through the control of myostatin-
mediated signaling is an attractive strategy since it involves 
manipulating a naturally occurring mechanism to control 
muscle mass. This study shows that a single injection of an 
AAV virus expressing a modified version of the MyoPPT 
is able to induce muscle growth in aged mice. Importantly, 
we show through our physiological based experiments that 
the hypertrophic muscle in aged mice is normal in terms 
of its ability to generate contraction force. The molecular 
profiling of key genes indicated that muscle mass has been 
increased through the normalization of proteasome-medi-
ated polypeptide breakdown to concentrations displayed by 
young mice that do not display any signs of aging.
Figure 3. Tibialis anterior gene expression in response to AAV8ProMyo treatment. (A) FoxO1. (B) MuRF1. (C) Atrogin-1. (D) Bnip3. (E) Beclin. (F) LC3b. 
(G) ATF4. (H) Cathepsin L. (I) Vps34. (J) p62. (K) Gadd34 (one-way analysis of variance; *p < .05, **p < .001, ***p < .0001). PPT = propeptide.
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This study examined the effect of expressing the myosta-
tin propeptide starting at 20-month-old animals. At this 
stage, the mice display characteristics of aging including 
loss in muscle mass (eg, 2 mg decrease in EDL weight 
between 7 and 20 months of age; see Amthor coworkers (21) 
and Collins-Hooper, 2013, unpublished data). It is interest-
ing that during the 7 weeks of the study, control-treated mice 
showed a slight increase in weight, but this was not in the 
muscle compartment. In contrast, AAV8MyoPPT treatment 
resulted in increased muscle mass in all entities examined. 
The small increase in the weight of control-treated animals 
could be due to fat deposition. However, fat weight changes 
did not reach significant levels, which could be due to tech-
nical difficulties during resection of the entire tissue.
One of the striking findings of this study is that increase 
in muscle mass brought about by neutralizing myostatin 
activity resulted in muscle that was capable of generating 
normal level of tension. This contrasts the situation in the 
myostatin null, which displays a significant drop in specific 
tension (21). The differences in terms of specific tension 
could be explained by considering key features of the kary-
oplasmatic theory—proposed in 1902 by Robert Hertwig—
which postulates that the nuclear to cytoplasmic ratio must 
be kept with certain values for the optimal functioning of a 
cell (see Richmond (37) for review of Hertwig’s work). The 
degree of fiber hypertrophy resulting from AAV8MyoPPT 
treatment does reach the levels caused by genetic deletion 
of myostatin. We suggest that following AAV8MyoPPT 
treatment, the nuclear to cytoplasmic ratio does not drop to 
the detrimental levels found in the knockout mouse model.
We have previously shown that AAV8MyoPPT treatment 
was able to induce robust growth to some but not all mus-
cles in young mice. That work was conducted on mice of 6 
weeks of age treated for 8 weeks and reported an increase 
in the weights of the TA, gastrocnemius, and EDL of 25%, 
27%, and 15% respectively. The soleus did not increase 
mass in a statistically significant manner (20). However, in a 
study using essentially the same reagents by an independent 
laboratory reported that the AAV8MyoPPT was effective in 
young mice but not in adult mice (38). This leads to the 
hypothesis that the intervention window for inducing mus-
cle growth by antagonizing the action of myostatin may be 
limited to relatively early postnatal life. However, this study 
and that of others suggest that this conclusion is incorrect 
as the attenuation of myostatin-mediated signaling through 
at least two approaches leads to increased muscle mass in 
aged mice. The ultimate basis for the success of these strat-
egies must rely on the age-related increased expression of 
myostatin. Some studies have shown no change in myosta-
tin with aging, whereas others have actually reported a 
decrease myostatin transcript (39,40). However, a recent 
study has shown for the first time an increase in both mRNA 
and myostatin protein in an aged human cohort (23). Many 
of the spurious results can be attributed to using nonspecific 
Figure 4. AAV8ProMyo injection in aged mice and EDL muscle contractile properties. (A) Maximum twitch force (mN). (B) Specific twitch force (maximum 
twitch tension normalized against muscle wet weight; N/g). (C) Maximum tetanic force (mN) (Student’s t test; *p < .01). (D) Specific tension (maximum tetanic ten-
sion normalized against muscle wet weight, n = 6 for each cohort). AAV = adeno-associated virus; EDL = extensor digitorum longus; PPT = propeptide.
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reagents especially antibodies purporting to be specific to 
myostatin.
Our previous study reported an increase in mass of 25%, 
27%, and 15% for the TA, gastrocnemius, and EDL, respec-
tively, and a nonsignificant enlargement of 13% for the soleus 
in 14-week-old mice (20). Here, we report significant mass 
gains of 7%, 16%, 21%, and 17% for the TA, gastrocne-
mius, EDL, and soleus, respectively, in 87-week-old mice. 
Therefore, two muscles have increased mass to a greater 
extent in old mice (EDL and soleus) and two display smaller 
increases (TA and gastrocnemius). Although it is beyond 
doubt that the AAV8MyoPPT treatment has induced increases 
in mass of all examined muscles in aged animals, the mecha-
nisms that control the relative growth muscles are not easy 
to pin down using this set of data due to the differences in 
genetic background of the mice used in the two studies.
Two recent studies have used a protocol of multiple anti-
myostatin antibody injections to increase muscle mass in 
aged mice. The results from those studies and findings 
reported here are worthy of comparison. The study of 
LeBrasseur and coworkers deployed a weekly injection 
regime of a high (25 mg/kg) of the PF-345, an anti-myosta-
tin antibody, on 24-month-old mice for 4 weeks (41). The 
mice in their study did not increase their body weights but 
did show muscle growth (gastrocnemius had increased 
in mass by 12%). Murphy and colleagues (42) used the 
same antibody at a lower dose (10 mg/kg) for 14 weeks on 
18-month-old mice and reported an increase in the mass of 
soleus, gastrocnemius, and quadriceps of 18%, 8%, and 9%, 
respectively. However, the EDL and TA did not show a sig-
nificant enlargement. Interestingly, both antibody regimes 
induced an increase in an oxidative profile and, in the study 
of Murphy and colleagues, a fiber type shift toward IIA. 
In contrast, we have shown that a single injection of the 
AAV8MyoPPT treatment leads to significantly increased 
enlargement of all muscles examined (EDL: 21%; gastroc-
nemius: 16%; soleus: 17%; and TA: 7%). These differences 
could be attributed to a number of reasons. It is likely that 
the differing structures of the two molecules is going to 
impact on the degree of tissue infiltration by the antagoniz-
ing molecule influenced through their interaction with the 
local connective tissue, whose composition differs based on 
the muscle fiber profile. Alternatively, the MyoPPT could 
neutralize proteins in addition to myostatin, which share 
functional and structural homology, for example, activin. 
Finally, the differences in efficacy could simply be due to 
the delivery protocol. We have used a viral method that leads 
to infection of cells and the sustained production of the neu-
tralizing agent, which may attain higher concentrations of 
the active molecule compared to the injection procedures.
However, one major difference in the outcomes of the 
antibody-based studies and this investigation is that con-
cerning the effect on the metabolic profile of muscle. We 
show that AAV8MyoPPT treatment leads to a decrease in the 
number of SDH-positive fibers, whereas antibody-mediated 
myostatin leads to an increase in the oxidative profile. Our 
results are in agreement with the phenotype of the myosta-
tin null mouse, dog, and cattle breeds, which all display 
increased number of glycolytic fibers (21). Interestingly, we 
were unable to detect a change in the myosin heavy chain 
profile toward a fast phenotype, even though there was a 
change in terms of the metabolic profile. This finding can be 
explained by taking into account that SDH concentrations 
can be manipulated quite rapidly (43), for example, over a 
few days through exercise regimes, whereas MHC turnover 
rates are in the order of many weeks (44).
The mechanism by which AAV8MyoPPT treatment 
results in increased muscle growth in aged animals seems 
to be similar to that regulated by the anti-myostatin anti-
body. In both cases, there was a decrease in the expression 
of MuRF1 and Atrogin-1 key muscle E3 ubiquitin ligases 
(27). However, we also report that aged muscle has an 
increased expression of FoxO1, which is able to induce not 
only proteasome-mediated degradation but also autophagy. 
Here, we show that there is an increase in both major muscle 
E3 ubiquitin ligases (MuRF1 and Atrogin-1) in aged mus-
cle compared with young muscle. Furthermore, the expres-
sion of both these genes is significantly reduced through 
AAV8MyoPPT treatment, suggesting that suppression of 
protein breakdown through the proteasome should be tar-
geted to develop antisarcopenic regimes. In contrast, we did 
not find a strong case for autophagy being clearly activated 
at a greater level in aged muscle, which is in agreement with 
numerous other studies. Indeed this has led some to suggest 
that autophagy plays a tissue-specific role during aging with 
some organs being more susceptible to damage through this 
mechanism (eg, liver and heart (45)) than others, possibly 
including skeletal muscle (46).
Myostatin is firmly established as a negative regulator of 
muscle growth. However, there is less agreement about how 
this activity is mediated. One school of thought is that it acts 
to suppress the activity of skeletal muscle stem cells (47). 
In contrast, others have conclusively shown that myostatin 
inhibits muscle enlargement and regeneration by control-
ling protein synthesis and breakdown in myofibers, through 
a mechanism largely if not wholly independent of satellite 
cells (48,49). These differing modes of action will have 
profound implication in terms of using myostatin antago-
nists to treat sarcopenia since we and others have shown 
that the number of stem cells declines drastically with age 
(50). Therefore, any mechanism promoting muscle growth 
though the activation of resident satellite cells is likely to 
be less efficacious with age. However, an elegant genetic-
based study has recently shown that ablation of satellite 
cells does not prevent muscle hypertrophy in the absence 
of myostatin. Therefore, we suggest that the major means 
of muscle enlargement has been brought about in this study 
is through an acellular hypertrophic response. Therefore, 
myostatin inhibition offers an attractive means to increase 
muscle mass not only when a depletion of satellite cells 
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occurs in an aging context but also in a spectrum of muscle 
diseases in which this population is diminished.
In summary, a striking level of muscle growth is induced 
by antagonizing myostatin signaling by the overexpression 
of the myostatin propeptide in aged mice. This work shows 
that aged muscle can be induced to undergo an increase in 
mass, and that the resultant tissue is capable of generat-
ing normal levels of force. We demonstrate that the muscle 
grew by increasing the size of existing fibers and was not 
likely to dependent on resident stem cells. Furthermore, we 
showed that the muscle had decreased its oxidative pro-
file, which would lend itself to greater glucose use. These 
manifestations imply that myostatin propeptide halts and 
reverses the adverse effects of sarcopenia in terms of mus-
cle mass and the metabolic changes associated with aging 
muscle (37).
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